Interestingly, McGuire et al. observed a LRR rate of 1.7% for patients with luminal A disease after 53-month follow-up, with LRR rates of 3.3% in those with luminal B disease (albeit limited in that they included HER2+cancers). This evidence concerns the gene ERBB2 and cancer.